Login to Your Account



Zealand's Lixisenatide Hits Mark in Phase III Combo Trial

By Cormac Sheridan


Wednesday, October 6, 2010
Lixisenatide, the Type II diabetes molecule discovered by Zealand Pharma A/S, met the primary endpoint in the first Phase III combination trial. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription